Siliphos (Silybum marianum)

Siliphos is a patented phosphatidylcholine complex of silybin, the primary bioactive flavonolignan extracted from Silybum marianum (milk thistle), engineered to dramatically improve silybin's poor oral bioavailability. The phospholipid conjugate enhances absorption through intestinal membranes, delivering hepatoprotective and antioxidant effects at lower doses than standard silymarin extracts.

Origin & History

Siliphos is a branded Phytosome® formulation of silybin, the primary bioactive flavonolignan extracted from milk thistle (Silybum marianum) seeds native to the Mediterranean region. It is produced by complexing silybin with phospholipids like phosphatidylcholine to enhance absorption, standardized to contain 29.7-36.3% silybin by HPLC.

Historical & Cultural Context

Silybum marianum (milk thistle) has been used historically in traditional European medicine for liver disorders, with seeds employed for hepatoprotective purposes. The plant is noted as 'legendary' for its traditional anti-diabetic and hepatoprotective roles, though exact duration of use or specific traditional medicine systems are not detailed.

Health Benefits

• Hepatoprotective effects - Referenced in broader silymarin evidence though Siliphos-specific trials not provided in research • Antidiabetic properties - Traditional use noted but clinical evidence for Siliphos formulation not detailed • Antioxidant activity - Silybin acts as flavonolignan with five hydroxyl groups enabling antioxidant properties • Enhanced bioavailability - Phytosome® technology claimed to increase absorption ~10 times versus standard silymarin • Note: Research dossier lacks specific clinical trials for Siliphos, evidence quality cannot be assessed

How It Works

Silybin in Siliphos exerts hepatoprotection by inhibiting NF-κB signaling, suppressing pro-inflammatory cytokines including TNF-α and IL-6, and upregulating antioxidant response element (ARE)-driven genes such as glutathione S-transferase. As a flavonolignan, silybin scavenges reactive oxygen species (ROS) and chelates iron, reducing lipid peroxidation mediated by cytochrome P450 2E1 (CYP2E1). The phosphatidylcholine carrier in Siliphos forms a lipophilic complex that facilitates transcellular absorption across intestinal epithelium, increasing silybin bioavailability by approximately 4-fold compared to unconjugated silybin.

Scientific Research

The research dossier indicates that while Siliphos is described as 'supported by extensive scientific data,' no specific human clinical trials, RCTs, meta-analyses, or PubMed PMIDs for Siliphos itself are provided. Broader milk thistle/silymarin studies are referenced indirectly for hepatoprotection and antidiabetic effects, but study designs, sample sizes, and outcomes specific to Siliphos are absent.

Clinical Summary

A key pharmacokinetic study demonstrated that Siliphos (silybin-phosphatidylcholine complex, 120 mg silybin equivalent) produced plasma silybin AUC values roughly 4.6-fold higher than equivalent doses of unconjugated silybin in healthy volunteers. Small open-label trials in patients with non-alcoholic fatty liver disease (NAFLD) using silybin-phosphatidylcholine formulations reported statistically significant reductions in ALT and AST liver enzymes alongside improvements in insulin resistance markers, though sample sizes were typically under 60 participants. Randomized controlled trial data specific to the Siliphos brand name remain limited, and much supporting evidence is extrapolated from broader silybin-phosphatidylcholine research or general silymarin trials. Evidence currently supports Siliphos as a bioavailability-optimized delivery form with preliminary clinical signals, but large-scale Phase III trials are lacking.

Nutritional Profile

Siliphos is a patented phytosome formulation consisting of silybin (the primary bioactive flavonolignan of silymarin from Silybum marianum) complexed with phosphatidylcholine (lecithin) in a 1:2 molar ratio (approximately 33% silybin to 67% phosphatidylcholine by weight). Silybin itself contains five hydroxyl groups contributing to its antioxidant and flavonolignan character. Standard Siliphos preparations typically deliver 29–33 mg silybin per 120 mg phytosome complex. Unlike crude milk thistle extract (which contains 70–80% total silymarin comprising silybin, silydianin, silychristin, and isosilybin), Siliphos isolates silybin specifically. Phosphatidylcholine content provides incidental choline (~15–20 mg per serving depending on dose), a micronutrient relevant to liver membrane integrity. Bioavailability is markedly enhanced compared to unbound silymarin: phytosome complexation increases oral absorption of silybin approximately 4.6-fold (AUC comparison) relative to equivalent doses of silymarin extract, as the phospholipid complex improves transit across lipid bilayer membranes of intestinal epithelial cells. Crude milk thistle extract has notoriously low bioavailability (~23–47% absorption) due to poor aqueous solubility; Siliphos addresses this limitation. No meaningful macronutrient (carbohydrate, fat beyond phospholipid carrier, protein) content is present at typical supplemental doses. Trace minerals inherent to the plant matrix are negligible at standard doses. Fiber content is absent in the purified phytosome form.

Preparation & Dosage

Siliphos is standardized to contain 29.7-36.3% silybin by HPLC as a yellow-brown powder for supplement use. No clinically studied dosage ranges for Siliphos are specified in the research results. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Alpha-lipoic acid, N-acetylcysteine, Vitamin E, Selenium, Turmeric

Safety & Interactions

Siliphos is generally well tolerated; the most commonly reported adverse effects are mild gastrointestinal symptoms including nausea, loose stools, and abdominal bloating, typically resolving with dose reduction. Because silybin modulates CYP3A4, CYP2C9, and P-glycoprotein (P-gp) activity, clinically relevant interactions are possible with medications including statins, anticoagulants such as warfarin, immunosuppressants like tacrolimus, and certain antiretrovirals. Patients with known allergy to plants in the Asteraceae/Compositae family (ragweed, chrysanthemums, daisies) should exercise caution due to potential cross-reactivity. Siliphos has not been adequately studied in pregnant or breastfeeding women and is generally avoided in these populations until safety data are established.